Cargando…

Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine

BACKGROUND: SARS-CoV-2 breakthrough infections after complete vaccination are increasing whereas their determinants remain uncharacterized. METHODS: We analyzed two cases of post-vaccination SARS-CoV-2 infections by α and β variants, respectively. For each participant both humoral (binding and neutr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallais, Floriane, Gantner, Pierre, Planas, Delphine, Solis, Morgane, Bruel, Timothée, Pierre, Florian, Soulier, Eric, Rossolillo, Paola, Fourati, Slim, Sibilia, Jean, Schwartz, Olivier, Fafi-Kremer, Samira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905643/
https://www.ncbi.nlm.nih.gov/pubmed/35281046
http://dx.doi.org/10.3389/fimmu.2022.790212
_version_ 1784665233978032128
author Gallais, Floriane
Gantner, Pierre
Planas, Delphine
Solis, Morgane
Bruel, Timothée
Pierre, Florian
Soulier, Eric
Rossolillo, Paola
Fourati, Slim
Sibilia, Jean
Schwartz, Olivier
Fafi-Kremer, Samira
author_facet Gallais, Floriane
Gantner, Pierre
Planas, Delphine
Solis, Morgane
Bruel, Timothée
Pierre, Florian
Soulier, Eric
Rossolillo, Paola
Fourati, Slim
Sibilia, Jean
Schwartz, Olivier
Fafi-Kremer, Samira
author_sort Gallais, Floriane
collection PubMed
description BACKGROUND: SARS-CoV-2 breakthrough infections after complete vaccination are increasing whereas their determinants remain uncharacterized. METHODS: We analyzed two cases of post-vaccination SARS-CoV-2 infections by α and β variants, respectively. For each participant both humoral (binding and neutralizing antibodies) and cellular (activation markers and cytokine expression) immune responses were characterized longitudinally. RESULTS: The first participant (P1) was infected by an α variant and displayed an extended and short period of viral excretion and symptom. Analysis of cellular and humoral response 72 h post-symptom onset revealed that P1 failed at developing neutralizing antibodies and a potent CD4 memory response (lack of SARS-CoV-2 specific CD4(+)IL-2(+) cells) and CD8 effector response (CD8(+)IFNγ(+) cells). The second participant (P2) developed post-vaccination SARS-CoV-2 infection by a β variant, associated with a short period of viral excretion and symptoms. Despite displaying initially high levels and polyfunctional T cell responses, P2 lacked initial β-directed neutralizing antibodies. Both participants developed and/or increased their neutralization activity and cellular responses against all variants, namely, β and δ variants that lasts up to 3 months after breakthrough infection. CONCLUSIONS: An analysis of cellular and humoral response suggests two possible mechanisms of breakthrough infection: a poor immune response to vaccine and viral evasion to neutralizing antibodies.
format Online
Article
Text
id pubmed-8905643
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89056432022-03-10 Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine Gallais, Floriane Gantner, Pierre Planas, Delphine Solis, Morgane Bruel, Timothée Pierre, Florian Soulier, Eric Rossolillo, Paola Fourati, Slim Sibilia, Jean Schwartz, Olivier Fafi-Kremer, Samira Front Immunol Immunology BACKGROUND: SARS-CoV-2 breakthrough infections after complete vaccination are increasing whereas their determinants remain uncharacterized. METHODS: We analyzed two cases of post-vaccination SARS-CoV-2 infections by α and β variants, respectively. For each participant both humoral (binding and neutralizing antibodies) and cellular (activation markers and cytokine expression) immune responses were characterized longitudinally. RESULTS: The first participant (P1) was infected by an α variant and displayed an extended and short period of viral excretion and symptom. Analysis of cellular and humoral response 72 h post-symptom onset revealed that P1 failed at developing neutralizing antibodies and a potent CD4 memory response (lack of SARS-CoV-2 specific CD4(+)IL-2(+) cells) and CD8 effector response (CD8(+)IFNγ(+) cells). The second participant (P2) developed post-vaccination SARS-CoV-2 infection by a β variant, associated with a short period of viral excretion and symptoms. Despite displaying initially high levels and polyfunctional T cell responses, P2 lacked initial β-directed neutralizing antibodies. Both participants developed and/or increased their neutralization activity and cellular responses against all variants, namely, β and δ variants that lasts up to 3 months after breakthrough infection. CONCLUSIONS: An analysis of cellular and humoral response suggests two possible mechanisms of breakthrough infection: a poor immune response to vaccine and viral evasion to neutralizing antibodies. Frontiers Media S.A. 2022-02-23 /pmc/articles/PMC8905643/ /pubmed/35281046 http://dx.doi.org/10.3389/fimmu.2022.790212 Text en Copyright © 2022 Gallais, Gantner, Planas, Solis, Bruel, Pierre, Soulier, Rossolillo, Fourati, Sibilia, Schwartz and Fafi-Kremer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gallais, Floriane
Gantner, Pierre
Planas, Delphine
Solis, Morgane
Bruel, Timothée
Pierre, Florian
Soulier, Eric
Rossolillo, Paola
Fourati, Slim
Sibilia, Jean
Schwartz, Olivier
Fafi-Kremer, Samira
Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
title Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
title_full Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
title_fullStr Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
title_full_unstemmed Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
title_short Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
title_sort case report: evolution of humoral and cellular immunity in two covid-19 breakthrough infections after bnt162b2 vaccine
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905643/
https://www.ncbi.nlm.nih.gov/pubmed/35281046
http://dx.doi.org/10.3389/fimmu.2022.790212
work_keys_str_mv AT gallaisfloriane casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT gantnerpierre casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT planasdelphine casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT solismorgane casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT brueltimothee casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT pierreflorian casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT souliereric casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT rossolillopaola casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT fouratislim casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT sibiliajean casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT schwartzolivier casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine
AT fafikremersamira casereportevolutionofhumoralandcellularimmunityintwocovid19breakthroughinfectionsafterbnt162b2vaccine